CompletedPhase 4

Low-dose Ketamine and Postpartum Depression in Parturients With Prenatal Depression

NCT03336541 · Peking University First Hospital

Closed to entry

Status

Not accepting participants

Phase 4

Phase

Target enrolment

Study sites

Outside the US

What it is testing

Summary

Postpartum depression is common in mothers early after childbirth and produces harmful effects not only on mothers, but also on infants and young children. Parturients with prenatal depression are at increased of postpartum depression. Low-dose ketamine can be used for antidepressant therapy. We hypothesize that low-dose ketamine has a therapeutic effect on parturients with prenatal depression. This study is designed to investigate whether low-dose ketamine administered during cesarean delivery can decrease the incidence of postpartum depression in parturients with prenatal depression.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

The score of postpartum depression at 48 hous after childbirth.
Measured over At 48 hours after delivery.

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 45 Years

Ages

FEMALE

Sex

Not accepted

Healthy volunteers

Inclusion Criteria: * Parturients with age from 18 to 45 years and scheduled for elective cesarean delivery; * Prenatal depression score (EPDS) of 10 or higher; * Provide written informed consents. Exclusion Criteria: * Refused to participate in the study; * History of schizophrenia or other disease that prevent normal communication before delivery; * Presence of contraindications to neuraxial anesthesia, including central nervous system diseases (such as poliomyelitis), spinal diseases (such as spinal canal tumor, lumbar disc prolapse, history of spinal trauma), systemic infection (such as sepsis, bacteremia), local infection in the site of puncture, or coagulopathy; * Severe complications during pregnancy (such as severe preeclampsia, placenta accreta, HELLP syndrome); * Severe comorbidity before pregnancy (such as severe cardiac dysfunction); * Scheduled to undergo cesarean delivery under general anesthesia; * Other reasons that are considered unsuitable for study participation.

Where

1 study site

Facility	City	Region	Country
Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital	Beijing	Beijing Municipality	China

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT03336541 on ClinicalTrials.gov →

Last updated in the registry 2021-12-13. Registry records change; this page reflects the data build of 2026-08-25.

Where this trial sits

Substance

Ketamine

Indication

All 7 trials from Peking University First Hospital →